Dr. Mike Sharma and Dr. C. Michael Gibson discuss the results of the phase III OCEANIC-STROKE Trial
In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by […]
Clinical Trial Results
In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by […]